AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Richard Tren and Roger Bate, "Brazil's AIDS Program: A Costly Success," AEI Health Policy Outlook, 2006 (aei.org)
AEI fellow Roger Bate and Richard Tren, Director of Africa Fighting Malaria, conclude that Brazil's success could prove detrimental to future generations worldwide.
Brazil has reduced AIDS mortality and incidence considerably and is on course to meet its target for AIDS incidence of ten cases per 100,000 in 2006, down from 14.2 per 100,000 in 2000. It has done this by producing cheap generic versions of anti-retroviral therapy (ART) drugs and by securing significant discounts for patented ART. For instance, Brazil has used several flexibilities in the Trade Related Aspects of Intellectual Property Rights (TRIPS) agreement to issue licenses to allow state-run manufacturer Instituto Far-Manguinhos to produce generic versions of ART drugs patented by Abbott, Merck, and Roche Laboratories.
Despite the success of these tactics in combating AIDS now, Brazilian-produced drugs are not equivalent to ...